SI1181294T1 - Novel derivatives and analogues of galanthamin - Google Patents

Novel derivatives and analogues of galanthamin

Info

Publication number
SI1181294T1
SI1181294T1 SI200130081T SI200130081T SI1181294T1 SI 1181294 T1 SI1181294 T1 SI 1181294T1 SI 200130081 T SI200130081 T SI 200130081T SI 200130081 T SI200130081 T SI 200130081T SI 1181294 T1 SI1181294 T1 SI 1181294T1
Authority
SI
Slovenia
Prior art keywords
galanthamin
analogues
novel derivatives
derivatives
novel
Prior art date
Application number
SI200130081T
Other languages
English (en)
Slovenian (sl)
Inventor
Ulrich Jordis
Johannes FR�HLICH
Matthias Treu
Manfred Hirnschall
Laszlo Czollner
Beate K�LZ
Stefan Welzig
Original Assignee
Sanochemia Pharmazeutica Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanochemia Pharmazeutica Aktiengesellschaft filed Critical Sanochemia Pharmazeutica Aktiengesellschaft
Publication of SI1181294T1 publication Critical patent/SI1181294T1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/94—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom spiro-condensed with carbocyclic rings or ring systems, e.g. griseofulvins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Furan Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
SI200130081T 2000-03-31 2001-03-22 Novel derivatives and analogues of galanthamin SI1181294T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AT5462000 2000-03-31
AT2382001 2001-02-15
PCT/AT2001/000082 WO2001074820A1 (de) 2000-03-31 2001-03-22 Neue derivate und analoga von galanthamin

Publications (1)

Publication Number Publication Date
SI1181294T1 true SI1181294T1 (en) 2004-08-31

Family

ID=25608130

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200130081T SI1181294T1 (en) 2000-03-31 2001-03-22 Novel derivatives and analogues of galanthamin

Country Status (26)

Country Link
US (2) US7166588B2 (enExample)
EP (1) EP1181294B1 (enExample)
JP (1) JP2003529602A (enExample)
CN (1) CN1380883A (enExample)
AT (1) ATE263171T1 (enExample)
AU (1) AU785385B2 (enExample)
BG (1) BG65134B1 (enExample)
BR (1) BR0105563A (enExample)
CA (1) CA2368966A1 (enExample)
CZ (1) CZ300160B6 (enExample)
DE (1) DE50101827D1 (enExample)
DK (1) DK1181294T3 (enExample)
ES (1) ES2215885T3 (enExample)
HK (1) HK1049832A1 (enExample)
HU (1) HUP0202233A3 (enExample)
IS (1) IS2287B (enExample)
MX (1) MXPA01012275A (enExample)
NO (1) NO326458B1 (enExample)
NZ (1) NZ516302A (enExample)
PL (1) PL202463B1 (enExample)
PT (1) PT1181294E (enExample)
RU (1) RU2241001C2 (enExample)
SI (1) SI1181294T1 (enExample)
SK (1) SK285909B6 (enExample)
TR (1) TR200400857T4 (enExample)
WO (1) WO2001074820A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4721386B2 (ja) * 2001-07-10 2011-07-13 第一三共株式会社 新規ガランタミン類縁体
MXPA04009254A (es) * 2002-03-25 2005-06-08 Sanochemia Pharmazeutika Ag Procedimiento para la obtencion de norgalantamina, derivados de norgalantamina asi como sus isomeros.
AT414125B (de) * 2003-09-29 2006-09-15 Sanochemia Pharmazeutika Ag Neue derivate des 4a,5,9,10,11,12-hexahydro- benzofuro(3a,3,2)(2) benzazepin, verfahren zu deren herstellung sowie deren verwendung zur herstellung von arzneimitteln
AT500143A1 (de) * 2004-04-22 2005-11-15 Sanochemia Pharmazeutika Ag Cholinesterase-inhibitoren in liposomen sowie deren herstellung und verwendung
US7877350B2 (en) * 2005-06-27 2011-01-25 Ab Initio Technology Llc Managing metadata for graph-based computations
DE602006015338D1 (de) * 2005-09-22 2010-08-19 Galantos Pharma Gmbh Cholinerge enhancer mit verbesserter durchgängigkeit durch die blut-hirn-schranke zur behandlung von krankheiten, die mit kognitiven störungen einhergehen
US20090253654A1 (en) 2005-09-22 2009-10-08 Galantos Pharma Gmbh Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment
WO2008022365A2 (de) * 2006-08-24 2008-02-28 Sanochemia Ltd. Mittel zum beeinflussen der wirkungen von organophosphorverbindungen und verwendung von galanthamin, dessen derivaten und analoga zum herstellen solcher mittel
CA2721007C (en) 2008-04-14 2014-04-29 Galantos Pharma Gmbh Derivatives of galantamine as pro-drugs for the treatment of human brain diseases
BG110141A (en) * 2008-05-23 2009-12-31 "Софарма" Ад GALANTAMINE DERIVATIVES, METHODS FOR THEIR PREPARATION AND USE
CN107066241B (zh) 2010-06-15 2021-03-09 起元技术有限责任公司 用于动态加载基于图的计算的系统和方法
WO2013160728A1 (en) 2012-04-26 2013-10-31 Alma Mater Studiorum - Universita' Di Bologna Dual targeting compounds for the treatment of alzheimer's disease
US10108521B2 (en) * 2012-11-16 2018-10-23 Ab Initio Technology Llc Dynamic component performance monitoring
CN106170762B (zh) 2013-12-05 2020-01-14 起元技术有限责任公司 管理包括子图的数据流图所用的接口
SG11201701662XA (en) 2014-09-02 2017-04-27 Ab Initio Technology Llc Visually specifying subsets of components in graph-based programs through user interactions
WO2016036826A1 (en) 2014-09-02 2016-03-10 Ab Initio Technology Llc Compiling graph-based program specifications
US10657134B2 (en) 2015-08-05 2020-05-19 Ab Initio Technology Llc Selecting queries for execution on a stream of real-time data
US12006301B1 (en) 2021-05-13 2024-06-11 Florida A&M University And synthesis of dual 5-HT1A and 5-HT7 receptor ligands
CN116082352A (zh) * 2023-02-16 2023-05-09 西南交通大学 一种加兰他敏衍生物及其制备方法和用途
CN118908968B (zh) * 2024-10-09 2025-03-04 威胜生物医药(苏州)股份有限公司 一种加兰他敏中间体衍生物及其催化氧化制备方法
CN119528922B (zh) * 2024-11-22 2025-12-09 泰安汉威集团有限公司 一种氢溴酸加兰他敏关键杂质-氢溴酸表加兰他敏的手性合成方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3947445A (en) * 1974-05-09 1976-03-30 Stanford Research Institute Diazabicyclooctanes and diazabicycloheptanes
US4663318A (en) 1986-01-15 1987-05-05 Bonnie Davis Method of treating Alzheimer's disease
EP0363415B1 (en) 1987-05-04 2008-10-15 Davis, Bonnie Compounds for the treatment of alzheimer's disease
NL8800350A (nl) 1988-02-12 1989-09-01 Stichting Biomedical Research Synthetische galanthamine-derivaten, werkwijze voor het bereiden daarvan, en farmaceutische samenstellingen.
US4954502A (en) 1988-06-10 1990-09-04 Bristol-Myers Squibb Company 1-indolyalkyl-4-(substituted-pyridinyl)piperazines
US5336675A (en) * 1991-05-14 1994-08-09 Ernir Snorrason Method of treating mania in humans
US5153193A (en) * 1991-10-01 1992-10-06 Hoechst-Roussel Pharmaceuticals Incorporated Carbamate derivatives of 4-amino-3-isoxazolidinones, 3-amino-1-hydroxypyrrolidin-2-ones and 1-amino-1-cyclopropanecarboxylic acid analogs
US6323195B1 (en) 1993-10-15 2001-11-27 Aventis Pharmaceuticals Inc. Galanthamine derivatives as acetylcholinesterase inhibitors
US6323196B1 (en) 1993-10-15 2001-11-27 Aventis Pharmaceuticals Inc. Galanthamine derivatives as acetylcholinesterase inhibitors
US5428159A (en) * 1994-04-08 1995-06-27 Ciba-Geigy Corporation Method of manufacture of (-)-galanthamine in high yield and purity substantially free of epigalanthamine
AT401058B (de) 1994-10-21 1996-06-25 Waldheim Pharmazeutika Gmbh Verfahren zum herstellen von derivaten des 4a,5, 9,10,11,12,-hexahydro-6h-benzofuro(3a,-3,2-ef) (2)benzazepins
SK283877B6 (sk) * 1994-10-21 2004-04-06 Sanochemia Pharmazeutika Ag Spôsob výroby derivátov 4a,5,9,10,11,12,-hexahydro-6H- benzofuro[3a,3,2-ef][2]benzazepínu
US6407229B1 (en) 1994-10-21 2002-06-18 Sanochemia Pharmazeutika Ag Processes for the preparation of derivatives of 4a,5,9,10,11,12-hexahydro-6H-benzofuro-[3a,3,2-ef][2] benzazapine
GB9514821D0 (en) * 1995-07-19 1995-09-20 Sod Conseils Rech Applic Galanthamine derivatives
GB9519268D0 (en) 1995-09-21 1995-11-22 Chiroscience Ltd Preparation of alkaloids
AT403803B (de) 1996-04-19 1998-05-25 Sanochemia Ltd Neue benzazepinderivate, diese enthaltende arzneimittel und verwendung derselben zum herstellen von arzneimitteln
GB9716879D0 (en) * 1997-08-08 1997-10-15 Shire Int Licensing Bv Treatment of attention deficit disorders
AU1430099A (en) * 1998-12-01 2000-06-19 Sanochemia Pharmazeutika Aktiengesellschaft Use of galanthamine and galanthamine derivatives in the case of acute functionalbrain damage
AT414125B (de) 2003-09-29 2006-09-15 Sanochemia Pharmazeutika Ag Neue derivate des 4a,5,9,10,11,12-hexahydro- benzofuro(3a,3,2)(2) benzazepin, verfahren zu deren herstellung sowie deren verwendung zur herstellung von arzneimitteln

Also Published As

Publication number Publication date
JP2003529602A (ja) 2003-10-07
US20030199493A1 (en) 2003-10-23
AU785385B2 (en) 2007-03-29
SK17022001A3 (sk) 2003-02-04
DE50101827D1 (de) 2004-05-06
CN1380883A (zh) 2002-11-20
NO20015857D0 (no) 2001-11-30
NZ516302A (en) 2004-02-27
PL352638A1 (en) 2003-09-08
ATE263171T1 (de) 2004-04-15
PL202463B1 (pl) 2009-06-30
SK285909B6 (sk) 2007-10-04
IS2287B (is) 2007-10-15
WO2001074820A1 (de) 2001-10-11
MXPA01012275A (es) 2003-06-24
CZ300160B6 (cs) 2009-02-25
BG65134B1 (bg) 2007-03-30
ES2215885T3 (es) 2004-10-16
EP1181294A1 (de) 2002-02-27
NO326458B1 (no) 2008-12-08
BG106155A (en) 2002-08-30
HK1045990A1 (en) 2002-12-20
TR200400857T4 (tr) 2004-06-21
CZ20014178A3 (cs) 2002-11-13
HUP0202233A3 (en) 2004-12-28
PT1181294E (pt) 2004-07-30
AU4208501A (en) 2001-10-15
NO20015857L (no) 2002-01-29
US7166588B2 (en) 2007-01-23
HK1049832A1 (zh) 2003-05-30
EP1181294B1 (de) 2004-03-31
US20070027138A1 (en) 2007-02-01
DK1181294T3 (da) 2004-08-02
CA2368966A1 (en) 2001-10-11
IS6174A (is) 2001-11-23
RU2241001C2 (ru) 2004-11-27
BR0105563A (pt) 2002-04-02
HUP0202233A2 (hu) 2002-11-28

Similar Documents

Publication Publication Date Title
SI1181294T1 (en) Novel derivatives and analogues of galanthamin
SE0000540D0 (sv) New compounds
JO2654B1 (en) Multiple aryl caroxa amides are useful as lipid - lowering agents
TW200510368A (en) Pharmaceutical compositions and combinations of novel non-imidazole compounds
DOP2001000151A (es) Derivados de imidazopirimidina y derivados de triazolopimidina.
YU83602A (sh) Derivati fenilglicina
BE2017C018I2 (enExample)
DE60336850D1 (en) Substituierte arylcyclopropylacetamide als glucokinaseaktivatoren
AU2003229953A8 (en) Phthalazinone derivatives
GB9919776D0 (en) Compoujnds
DE60135919D1 (de) Farnesyl transferase-hemmende 6-heterocyclylmethyl-chinolin und chinazol-derivate
PT1193270E (pt) Pirrolobenzodiazepinas
BG106585A (en) Kinase inhibitors as therapeutic agents
MXPA02012033A (es) Derivados de 2-aminocarbonil-9h-purina.
PL342113A1 (en) Sulphonamidic derivatives useful as precursors of aspartil protease inhibitors
CY1113648T1 (el) Παραγωγα πυριδινονης για θεραπεια αθηροσκληρωσης
GB0127903D0 (en) Improvements relating to organic compounds
DE60121461D1 (de) Kondensierte pyridoindolderivate
MXPA02012054A (es) Compuestos de dicetopiracina tetraciclica como inhibidores de la fosfodiesterasa v.
AU2001263278A1 (en) Cyclic gmp-specific phosphodiesterase inhibitors
MXPA03003942A (es) Compuestos bis-heterociclicos con actividad antitumoral y quimiosensibilizante.
IL150806A0 (en) Piperidine-and piperazine substituted n-hydroxyformamides as inhibitors of metalloproteinases
AP2002002547A0 (en) Calcilytic compounds.
EP1383511A4 (en) CALCILYTIC COMPOUNDS
GB0205327D0 (en) compounds